Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60
WHO grade II gliomas are uncommon in patients over the age of 60, and there is a lack in consensus regarding their management. We present molecular tumor characteristics as well as clinical outcomes in patients over the age of 60 undergoing surgical resection of a WHO grade II glioma.
After receiving IRB approval, patients were identified through the UCSF Brain Tumor Center. Pathologic diagnosis was completed using WHO 2016 grading criteria.
Twenty-six patients with a mean age of 66 years met inclusion criteria with a median follow-up of 5.2 years. Diagnoses included diffuse astrocytoma IDH-mutant (19.2%), diffuse astrocytoma IDH-wildtype (26.9%), Oligodendroglioma IDH-mutant and 1p/19q-codeleted (50%), and a rare case of mixed oligoastrocytoma (3.9%). 66% of astrocytoma IDH-wildtype tumors possessed TERT mutation. Median extent of resection was 75.4%. Progression-free (PFS) and overall survival (OS) were 23.5 and 62.6 months, respectively. Shorter PFS was associated with the astrocytoma IDH-wildtype subtype despite similar extent of resection and adjuvant treatment rates compared to the other subtypes. OS did not differ between subtypes. Malignant transformation and death were associated with larger preoperative and residual tumor volume.
Older patients with diffuse gliomas may safely undergo aggressive treatment with surgical resection and adjuvant therapy. Elderly patients with low grade gliomas have worse clinical outcomes compared to their younger counterparts. This may be due to an increased frequency of diffuse astrocytoma IDH-wildtype tumors in this age group.
KeywordsLow-grade glioma Surgical resection Elderly Old age
We would like to thank Jing Li for completing the search of the institutional database for patients qualifying for this study.
All authors have contributed significantly to the experimental design, analyses, interpretation of the data and writing of the manuscript.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
- 8.Davis FG, Freels S, Grutsch J et al (1998) Survival rates in patients with primary malignant brain tumors stratified by patient age and tumor histological type: an analysis based on Surveillance, Epidemiology, and End Results (SEER) data, 1973-1991. J Neurosurg 88:1–10. https://doi.org/10.3171/jns.1998.88.1.0001 CrossRefPubMedGoogle Scholar
- 10.Shaw E, Arusell R, Scheithauer B et al (2002) Prospective randomized trial of low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. J Clin Oncol 20:2267–2276. https://doi.org/10.1200/JCO.2002.09.126 CrossRefPubMedGoogle Scholar
- 15.Berger MS, Deliganis AV, Dobbins J, Keles GE (1994) The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74:1784–1791. https://doi.org/10.1002/1097-0142(19940915)74:6%3C1784::AID-CNCR2820740622%3E3.0.CO;2-D CrossRefPubMedGoogle Scholar
- 18.International Agency for Research on Cancer (2016) WHO Classification of Tumours of the Central Nervous System, 4th edn. World Health Organization, GenevaGoogle Scholar
- 19.National Center for Health Statistics (2017) Health, United States, 2016. HyattsvilleGoogle Scholar
- 21.Chi A, Batchelor T (2007) Low-grade gliomas in older patients: a malignant tumor? Neuro Oncol 9:545Google Scholar